Glaxo Ziagen/AZT/3TC Combo Appropriate For Second-Line Use, Cmte. Says
Executive Summary
A triple nucleoside combination containing Glaxo Wellcome's Ziagen plus AZT and 3TC would be useful as a second-line therapy in HIV patients for whom protease inhibitors are contraindicated, members of FDA's Antiviral Drugs Advisory Committee suggested Nov. 2.
You may also be interested in...
GSK’s Ziagen Relabeled: REMS And The Path To Personalized Medicine
A relabeling of GlaxoSmithKline's HIV treatment Ziagen (abacavir sulfate) to recommend pharmacogenomic screening illustrates the potential for FDA's new drug safety tools to encourage the push towards personalized medicine
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011